Foley Hoag Represents HiFiBiO Therapeutics in Agreement Worth More Than $1.1B
Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
June 22, 2021
Foley Hoag LLP represented HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, in an agreement to exclusively license its Galectin-9 program, and grant an exclusive option to its CXCR5 and CCR8 programs, to biopharmaceutical company FibroGen, Inc. (Nasdaq: FGEN). Under the terms of the agreement, HiFiBiO will receive a $25 million upfront payment, and up to a total of $1.1 billion in additional milestone payments across all three programs, plus royalties. The partnership represents significant validation of HiFiBiO’s Drug Intelligent Science (DIS™) approach and deep expertise in disease biology and translation science, and plays a key role in advancing next-generation therapies for patients with cancer and autoimmune disease.
HiFiBiO is an emerging clinical-stage multinational company with laboratories in Cambridge, Mass., Paris, Shanghai, Hong Kong and Hangzhou. The company is transforming the field of immunotherapy by combining proprietary single-cell profiling technologies with advanced data intelligence and deep knowledge of immune system biology. HiFiBiO is actively working to address unmet medical needs around the world through its own innovative pipeline programs and open-innovation partnerships with world-renowned industry and academic researchers.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.